Certainly, in the 60's, 70's and 80's, classic alkylators such as cyclophosphamide were used very commonly in germ cell tumor regimens. Radiation therapy has been largely eliminated in patients with non-seminomatous testicular tumors. Ports and doses have been limited in patients with seminoma including elimination of prophylactic mediastinal radiation therapy. The recognition that any treatment, even two cycles of chemotherapy or low dose radiation therapy, is likely to be associated with a definable risk of second malignancies should cause careful consideration of the relative benefits of such therapy. It should provide the impetus and mandate for long term follow up tied to detailed accounting of treatments received for testicular cancer.
All cancer therapies can perturb the quality and quantity of survivorship.
The tremendous success of therapy in testicular cancer should not dim the recognition of the second malignancies engendered by treatment or diminished responsibility for careful reporting of both short and long term treatment results. Since there really aren't any general screening tests that would be useful in this regard, your best defense is a regular checkup and personal knowledge of early warning signs should The Beast decide to rear his ugly head again.